01—Abstract
Summary
Summary of the 10-Q filed July 28, 2026. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation's 10-Q for the quarter ended June 30, 2026 reports total revenues of $1.67 billiona for the second quarter, up from $1.22 billion a year earlier, and net income of $585.6 million, or $2.81 per diluted share, compared with $405.0 million, or $2.04 per diluted share, in the prior-year quarter.
Net sales were $1.49 billionb, including a one-time, non-cash $246.0 million benefit from the reversal of previously established accruals after Incyte reached an agreement with CMS resolving litigation over the Medicaid rebate treatment of OPZELURA. JAKAFI net sales were $816.7 million for the quarter, and OPZELURA net sales were $449.7 million, which includes that $246.0 million benefit. Cash, cash equivalents and marketable securities totaled $4.5 billion at June 30, 2026, and net cash provided by operating activities was $877.0 million for the six months.
Research and development expense was $516.9 millionc for the quarter. The company also notes a subsequent event: it completed the acquisition of Vega Therapeutics on July 6, 2026 for $1.25 billion in cash, with up to $750.0 million in additional sales-based payments, and expects to expense the upfront consideration as in-process research and development in the third quarter of 2026.
The filing also describes pipeline and regulatory activity, including the May 2026 FDA approval of JAKAFI XR, the planned povorcitinib filings, and Phase 3 programs for INCA033989 and tafasitamab. JAKAFI's composition-of-matter patents are noted as expiring in 2028, and the filing states that generic challengers have filed ANDAs and Paragraph IV certifications against JAKAFI and OPZELURA, with several of the JAKAFI actions settled and others still pending.
02—Key points
Key Highlights
- Total revenues were $1,674.0 million for Q2 2026 versus $1,215.5 million in Q2 2025; net sales were $1,488.1 million.
- Net income was $585.6 million ($2.81 diluted EPS) for Q2 2026 versus $405.0 million ($2.04 diluted EPS) a year earlier.
- Q2 2026 OPZELURA net sales include a one-time, non-cash $246.0 million benefit tied to the CMS Medicaid rebate litigation settlement.
- JAKAFI net sales were $816.7 million in Q2 2026 versus $763.8 million, with the filing citing a paid demand increase of 9%.
- Cash, cash equivalents and marketable securities totaled $4.5 billion at June 30, 2026; the company had no outstanding borrowings under its $500.0 million revolving credit facility.
- Subsequent to quarter-end, Incyte completed the $1.25 billion cash acquisition of Vega Therapeutics on July 6, 2026, with up to $750.0 million in additional sales-based payments.
- Operating cash flow for the six months ended June 30, 2026 was $877.0 million, compared with $310.8 million in the prior-year period.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2026, Incyte kept $0.35.
- Revenue$1.67B100.0%
- Cost of revenue−$105.0M6.3%
- Gross profit$1.57B93.7%
- Operating costs−$871.2M52.0%
- Operating income$697.9M41.7%
- Interest, other & tax−$112.3M6.7%
- Net income$585.6M35.0%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed July 28, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $1.67B$1.22B | +37.7% |
| Cost of Revenue | $104.96M$78.77M | +33.3% |
| Gross Profit | $1.57B$1.14B | +38.0% |
| R&D Expenses | $516.95M$494.92M | +4.5% |
| SG&A Expenses | $351.74M$331.02M | +6.3% |
| Operating Expenses | $976.14M$685.22M | +42.5% |
| Operating Income | $697.90M$530.31M | +31.6% |
| Net Income | $585.61M$405.00M | +44.6% |
| EPS (Basic) | $2.92$2.09 | +39.7% |
| EPS (Diluted) | $2.81$2.04 | +37.7% |
| Shares Outstanding (Basic) | 200.38M194.00M | +3.3% |
| Shares Outstanding (Diluted) | 208.22M198.74M | +4.8% |
05—Questions
Frequently Asked Questions
What drove the increase in Incyte's second-quarter 2026 revenue?
Total revenues rose to $1,674.0 million from $1,215.5 million. Net sales increased to $1,488.1 million from $1,059.4 million, driven by JAKAFI ($816.7 million), OPZELURA ($449.7 million, including the $246.0 million CMS-related benefit), NIKTIMVO ($60.3 million), MINJUVI/MONJUVI ($53.7 million) and ZYNYZ ($49.9 million). Product royalty revenues were $174.7 million versus $151.1 million.
How significant is the $246.0 million OPZELURA item?
The filing describes it as a one-time, non-cash benefit to net sales from reversing previously established accrual balances through March 31, 2026, tied to the agreement with CMS that CMS will not apply the line extension regulation to OPZELURA as if it were a line extension of JAKAFI. Excluding this amount, the filing states OPZELURA net sales increased with a volume increase of $48.2 million for the quarter, offset by a price decrease of $9.0 million, and the company expects an improvement to OPZELURA's gross-to-net going forward.
What is the impact of the Vega Therapeutics acquisition on future results?
Incyte paid $1.25 billion in cash for Vega, with up to $750.0 million in additional payments tied to specified sales milestones. The company expects to account for the deal as an asset acquisition and to record substantially all of the upfront consideration as research and development expense in the third quarter of 2026.
What risks does the filing highlight for JAKAFI?
The filing states that JAKAFI product sales are expected to begin declining upon the expiration of patent exclusivity in 2028. It also discloses that multiple generic manufacturers filed ANDAs and a Paragraph IV challenge; Incyte has settled litigation with several of them, and the actions against the others remain pending.
How strong is Incyte's liquidity position?
At June 30, 2026, cash and cash equivalents were $3,982.4 million and marketable securities were $553.4 million, totaling $4.5 billion. The company had no outstanding borrowings under its $500.0 million unsecured revolving credit facility, which matures in June 2027, and it stated that cash flow and existing resources are expected to be adequate for the foreseeable future.
06—Continue